Mexico City /
The Federal Commission for the Protection against Sanitary Risks (Cofepris) approved the monotherapy developed in collaboration with Daiichi Sankyo, to care for people with HER2-positive and HER2-low advanced and metastatic breast cancer, who have received prior treatment, reported AstraZeneca Mexico.
“With this innovative therapy, a new era begins in the approach to this condition in Mexico, with unprecedented efficacy. Results from the phase III DESTINY-Breast03 trial showed that people with HER2-positive and HER2-low advanced and metastatic breast cancer who received this treatment had a 36 percent reduced risk of death and a 64 percent reduced risk of death. the risk of progression of the disease, increasing four times the possibility of living without the disease”.
In the country, the disease has increased its incidence and is one of the main causes of death.
In fact, in 2020 more than two million people were diagnosed globally with breast cancerrepresenting nearly 685,000 deaths and approximately one in five cases is considered HER2-positive.
“At AstraZeneca we have the ambition to develop a cure for cancer and that this disease is not synonymous with death, while we reinforce our commitment to Mexicans by challenging the limits of science and designing next-generation alternatives to redefine the approach of this disease.
“By having a 10-year pipeline, our goal is to consolidate one of the most diverse and innovative portfolios in the oncology industry. The monotherapy has been approved by Cofepris, it will begin the logistical process to introduce it to the country, so that it is available to Mexicans in the coming months”.
EHR
